-
MTSEA-biotin for Cysteine Accessibility Assays
2026-09-16
MTSEA-biotin enables covalent, affinity-assisted analysis of accessible cysteine residues. This guide connects thiol-reactive labeling with the RNAPII phosphorylation landscape revealed by FeaSion, helping researchers choose orthogonal assays without confusing structural accessibility with phosphorylation state.
-
TMEM16F Lipid Scrambling in Ferroptosis and Immunity
2026-09-15
Yang et al. identify TMEM16F-mediated phospholipid scrambling as a late-stage suppressor of ferroptosis that protects the plasma membrane from collapse. The study further shows that disabling this membrane-remodeling response can increase tumor immunogenicity and improve the effect of PD-1 blockade, providing a mechanistic link between ferroptotic membrane damage and immune rejection.
-
Nuclear cGAS Restricts L1 Retrotransposition
2026-09-15
The reference study identifies a nuclear cGAS–CHK2–TRIM41 pathway that limits LINE-1 retrotransposition by promoting ubiquitination and degradation of the L1 ORF2p protein. Its findings connect DNA damage signaling, post-translational protein control, and genome integrity, while providing a framework for interpreting L1 regulation in senescence and cancer biology.
-
Separating Growth Inhibition from Cell Death in Cancer
2026-09-14
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a more precise framework for distinguishing proliferative arrest from true cell killing, improving interpretation of dose–response experiments and translational cancer research workflows.
-
GI Microjet Delivery of mRNA-LNPs in Mice and Pigs
2026-09-14
The reference study shows that ingestible microjet devices can deliver mRNA-loaded lipid nanoparticles into gastric and intestinal tissue, producing measurable expression and biodistribution in both mice and minipigs. Its central contribution is evidence that gastrointestinal wall administration generates route-dependent exposure in plasma and lymph nodes, supporting further evaluation of needle-free delivery for mRNA therapeutics.
-
P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL
2026-09-13
The reference study identifies P2RX1 as a regulator of tyrosine kinase inhibitor sensitivity in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking excessive purinergic signaling to calcium/CaMKII activation, PI3K/Akt suppression, mitochondrial dysfunction, and intrinsic apoptosis. Its integrated molecular and functional design provides a framework for connecting pathway changes with measurable cell-death phenotypes in Ph+ ALL models.
-
Verteporfin Beyond PDT: A Mechanobiology Framework
2026-09-12
Verteporfin and CL 318952 can be interpreted through a mechanobiology lens that separates light-dependent cytotoxicity, autophagy inhibition, and cancer-cell stiffness. This guide connects Verteporfin assay design with the MRTFA–KCNMB1 findings that link ionic regulation to metastatic immune evasion.
-
Intravesical p21 mRNA–LNP Therapy in Bladder Cancer
2026-09-11
A 2026 FASEB Journal study developed chemically modified p21 mRNA packaged in lipid nanoparticles for catheter-based bladder delivery. The approach restored nuclear p21, inhibited tumor-cell proliferation, and reduced orthotopic bladder tumor growth while limiting systemic exposure, supporting localized tumor suppressor replacement as a translational strategy.
-
KN-62: A Causal CaMKII Assay Design Guide
2026-09-11
KN-62 is a selective CaMKII inhibitor for separating kinase-dependent signaling from upstream calcium-channel effects. This guide combines product chemistry, secretion and metabolism data, cell-cycle biology, and a calcium-channel reference study to build more discriminating assays.
-
Firefly Luciferase mRNA: Assay Workflows
2026-09-10
Build more reproducible transfection, gene expression, and cell viability workflows with a modified, ARCA-capped luciferase transcript. This guide connects practical assay setup with delivery lessons from recent mRNA vaccine research, while clearly separating validated product characteristics from optimization recommendations.
-
Nelfinavir Mesylate: Two-Pathway Assay Logic
2026-09-10
Nelfinavir Mesylate is more than an HIV-1 protease inhibitor: it is a useful probe for separating antiviral activity from DDI2-NFE2L1 control of ferroptosis. This guide presents a causality-focused assay framework for HIV replication suppression, proteostasis analysis, and HIV infection research.
-
AG-490 (JAK2/EGFR inhibitor) Assay Guide
2026-09-09
This scenario-based guide explains how AG-490 (JAK2/EGFR inhibitor), SKU A4139, can support controlled studies of JAK-STAT, EGFR, and MAPK signaling in viability, proliferation, and cytotoxicity workflows. It connects formulation, dose interpretation, exosomal SNORD52 research, and practical vendor-selection criteria without overstating pathway-specific evidence.
-
Dorsomorphin (Compound C): AMPK Assay Logic
2026-09-09
Dorsomorphin (Compound C) is more than an AMPK inhibitor: it is a useful perturbation tool for testing pathway causality in endothelial stress, metabolic, autophagy, and BMP studies. This guide explains how to interpret Compound C experiments, select orthogonal readouts, and avoid confusing pathway association with mechanism.
-
Puerarin Activates NO Signaling in Dental Follicle Cells
2026-09-08
The reference study shows that puerarin enhances osteogenic differentiation of rat dental follicle cells while increasing nitric oxide, cGMP, and related osteogenic markers. Pharmacological inhibition with L-NMMA reversed these effects, supporting a functional role for nitric oxide signaling in a periodontal regeneration model.
-
Predictive siRNA Codelivery with Netarsudil
2026-09-08
Slaughter and colleagues developed a quantitative screening and machine-learning framework for predicting when ionizable drugs can complex siRNA and support nanoparticle encapsulation. Netarsudil was identified as a high-performing candidate and experimentally evaluated with CTGF-targeting siRNA in fibrotic human trabecular meshwork cells, linking drug-enabled delivery with cytoskeletal and gene-expression readouts.